Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
Targeted therapies and clinical trial enrollment
11 evidence topics · 10 sources
Guideline recommendation of clinical trial enrollment for HLA-A∗02:01-negative patients
“For HLA-A∗02:01-negative patients, in the absence of a standard of care and depending on local resources, liver-directed therapies (PHP and IHP), anti-PD-1-based immunotherapies and clinical trial enrolment are the preferred therapeutic options [V, B].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Guideline statements on referral and access to clinical trials
“Patients should be referred for the recommendation of first-line locoregional or systemic treatment and discussion of UM clinical trials.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Metastatic disease remains an area of high unmet need and requires ambitious research collaborations.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients should have access to experimental treatments, including precision diagnostics and medicine and early-phase clinical trials for solid tumours.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Clinical trials as an option in metastatic and recurrent intraocular melanoma
MEK inhibitor selumetinib compared with chemotherapy: response, adverse events, and survival
“49% of patients treated with selumetinib achieved tumor regression, with 14% achieving an objective radiographic response to therapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Treatment-related adverse events were observed in 97% patients treated with selumetinib, with 37% requiring at least one dose reduction.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In this hypothesis-generating study of patients with advanced uveal melanoma, selumetinib compared with chemotherapy resulted in a modestly improved progression-free survival and response rate; however, no improvement in overall survival was observed.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Selumetinib plus dacarbazine versus placebo plus dacarbazine: phase 3 SUMIT trial of 129 participants
“The Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT) study was a phase III, double-blind trial” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“patients with metastatic uveal melanoma and no prior systemic therapy were randomly assigned (3:1) to selumetinib (75 mg twice daily) plus dacarbazine (1,000 mg/m2 intravenously on day 1 of every 21-day cycle) or placebo plus dacarbazine.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A total of 129 patients were randomly assigned to receive selumetinib plus dacarbazine (n = 97) or placebo plus dacarbazine (n = 32).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In the selumetinib plus dacarbazine group, 82 patients (85%) experienced a PFS event, compared with 24 (75%) in the placebo plus dacarbazine group (median, 2.8 v 1.8 months); the hazard ratio for PFS was 0.78 (95% CI, 0.48 to 1.27; two-sided P = .32).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In patients with metastatic uveal melanoma, the combination of selumetinib plus dacarbazine had a tolerable safety profile but did not significantly improve PFS compared with placebo plus dacarbazine.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Selumetinib with or without paclitaxel: randomized SelPac trial of 77 participants
“Seventy-seven patients with metastatic UM who had not received prior chemotherapy were randomised to selumetinib alone, or combined with paclitaxel with or without interruption in selumetinib two days before paclitaxel.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The median PFS in the combination arms was 4.8 months (95% CI: 3.8 - 5.6) compared with 3.4 months (2.0 - 3.9) in the selumetinib arm (HR 0.62 [90% CI 0.41 - 0.92], 1-sided p-value = 0.022).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“ORR was 14% and 4% in the combination and monotherapy arms respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“SelPac met its primary endpoint, demonstrating an improvement in PFS for combination selumetinib and paclitaxel.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“No improvement in OS was observed, and the modest improvement in PFS is not practice changing.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Systematic review of MEK inhibitors in metastatic uveal melanoma
“The overall response rate was available in five studies and ranged from 0 to 14% with an average of 2.5%.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The median progression-free survival ranged from 3.1 weeks to 16 weeks.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“UM is little responsive to MEK inhibition, regardless of the inhibiting agent and combination partner.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Our results do not support the use of MEK inhibitors in UM.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Protein kinase C inhibitor AEB071 monotherapy: phase 1 study of 153 participants
“Patients with metastatic UM (n = 153) were treated with AEB071 in a phase I, single-arm study.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Preliminary clinical activity was observed, with 3% of patients achieving a partial response and 50% with stable disease (median duration 15 weeks).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In conclusion, the protein kinase C inhibitor AEB071 was well tolerated, and modest clinical activity was observed in metastatic UM.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Sotrastaurin plus the MEK inhibitor binimetinib: phase 1b trial of 38 participants
“We therefore conducted this phase Ib study of the combination of sotrastaurin and binimetinib in patients with metastatic uveal melanoma” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Thirty-eight patients were treated across six dose levels.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“No patient achieved a radiographic response per RECIST v1.1.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Stable disease was observed in 60.5% of patients treated.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Sotrastaurin plus the PI3K-alpha inhibitor alpelisib: phase 1b study
“we conducted a phase Ib study to assess the safety of combined sotrastaurin, a PKC inhibitor, and alpelisib, a PI3K inhibitor.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients with metastatic uveal melanoma (n = 24) or GNAQ/11 mutant cutaneous melanoma (n = 1) were enrolled on escalating dose levels of sotrastaurin (100–400 mg BID) and alpelisib (200–350 mg QD).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Treatment-related adverse events (AE) occurred in 86% (any grade) and 29% (Grade 3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“No objective responses were observed, and median progression-free survival was 8 weeks (range, 3–51 weeks).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote